Matches in Wikidata for { <http://www.wikidata.org/entity/Q64601382> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q64601382 description "clinical trial" @default.
- Q64601382 description "ensayu clínicu" @default.
- Q64601382 description "klinisch onderzoek" @default.
- Q64601382 description "клінічне випробування" @default.
- Q64601382 name "Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis" @default.
- Q64601382 type Item @default.
- Q64601382 label "Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis" @default.
- Q64601382 prefLabel "Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis" @default.
- Q64601382 P1050 Q64601382-5AAAA2D5-7864-448B-B45C-A8608EE529EE @default.
- Q64601382 P1050 Q64601382-EA462623-743A-4E86-BC88-AF4264194135 @default.
- Q64601382 P1132 Q64601382-162E5B0D-864A-454E-87EC-C465A214354F @default.
- Q64601382 P1476 Q64601382-4FF918F5-8A35-4551-8108-27CB678C7276 @default.
- Q64601382 P17 Q64601382-0A52AC3E-8733-406C-A759-60E69D8F37F5 @default.
- Q64601382 P17 Q64601382-39077C34-936C-43EB-9AE5-5315FF326F34 @default.
- Q64601382 P17 Q64601382-567EF036-8648-4F3A-86CE-528D38214B33 @default.
- Q64601382 P17 Q64601382-56958192-736B-4EEA-A090-36D58A2F2968 @default.
- Q64601382 P17 Q64601382-593B4455-9D91-453C-8E12-2E9946CA56D4 @default.
- Q64601382 P17 Q64601382-8CFA9DC9-75EA-4E57-B0EF-AC9C4C9FF157 @default.
- Q64601382 P17 Q64601382-95219B70-55AF-47C9-8CC0-04EAB443F9F0 @default.
- Q64601382 P17 Q64601382-A0FDCCE5-79E1-4F40-AFC5-48777725AE1E @default.
- Q64601382 P17 Q64601382-AC66635F-EB86-46D0-85E1-B086917E9103 @default.
- Q64601382 P17 Q64601382-BA75A89C-FC6E-48D3-A949-BBFC1B7B4E01 @default.
- Q64601382 P17 Q64601382-F882903D-BFB9-4517-9DC2-4CF7923E1554 @default.
- Q64601382 P17 Q64601382-FD44DE46-70DB-41D5-A106-C95D545C7179 @default.
- Q64601382 P1813 Q64601382-9C13FF3A-0A1D-45FD-B998-62B9E65A877E @default.
- Q64601382 P2899 Q64601382-DEFC31BA-231E-4390-B7A3-FDF03F4615A3 @default.
- Q64601382 P3098 Q64601382-0137ACE0-9308-4055-9D03-71AACCF3DCA3 @default.
- Q64601382 P31 Q64601382-878776EB-02A0-458C-A615-8DECC4EAB58D @default.
- Q64601382 P580 Q64601382-597DB5E9-1362-4E52-8739-FEAF717DC463 @default.
- Q64601382 P582 Q64601382-760EADC0-A328-4BA6-8A8E-B7C5ABE2C5C9 @default.
- Q64601382 P6099 Q64601382-C355D037-1B69-4D0A-8A36-667AD62956B0 @default.
- Q64601382 P8363 Q64601382-D1D82E40-61D3-4C0A-994E-5E3C51359310 @default.
- Q64601382 P1050 Q229256 @default.
- Q64601382 P1050 Q988594 @default.
- Q64601382 P1132 "+740" @default.
- Q64601382 P1476 "A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis" @default.
- Q64601382 P17 Q145 @default.
- Q64601382 P17 Q16 @default.
- Q64601382 P17 Q17 @default.
- Q64601382 P17 Q218 @default.
- Q64601382 P17 Q28 @default.
- Q64601382 P17 Q29 @default.
- Q64601382 P17 Q30 @default.
- Q64601382 P17 Q36 @default.
- Q64601382 P17 Q38 @default.
- Q64601382 P17 Q408 @default.
- Q64601382 P17 Q55 @default.
- Q64601382 P17 Q664 @default.
- Q64601382 P1813 "CHRONOS" @default.
- Q64601382 P2899 "+18" @default.
- Q64601382 P3098 "NCT02260986" @default.
- Q64601382 P31 Q30612 @default.
- Q64601382 P580 "2014-09-01T00:00:00Z" @default.
- Q64601382 P582 "2015-08-01T00:00:00Z" @default.
- Q64601382 P6099 Q42824827 @default.
- Q64601382 P8363 Q78089383 @default.